The European Myeloma Network
(EMN)
The European Myeloma Network was established in 2003 by integrating 27 research institutions and 14 trial groups with
the intent to support development of novel diagnostics and therapies for multiple myeloma.
Now, EMN is legalised and ready to initiate and support co-operative clinical trials and laboratory research.
The Myeloma Stem Cell Network (MSCNET)
is part of EMN. It is supported by
EU's Sixth Framework Programme.
News
| EHA-13 Scientific Working Group “Multiple Myeloma” |
SWG Multiple Myeloma conducted a scientific meeting chaired by Pieter Sonneveld (Rotterdam, the Netherlands) and Hans E. Johnsen (Aalborg, Denmark). 35 attendants participated. The focus of the meeting was “The Myeloma Stem Cell” .
Hans E. Johnsen introduced the concept and the scientific background of the myeloma stem cell. Martin Perez Andres (Salamanca, Spain) addressed the B cell hierarchy in B cell malignancies and myeloma. Various B-cell compartments that may carry early clonal characteristics were defined.
Surinder Sahota (Southampton, United Kingdom) described molecular approaches to track the myeloma compartment and identify distinct profiles for pre-plasma cells that may belong to the myeloma clone. Pieter Sonneveld presented gene expression data of myeloma patients, and introduced the concept of a molecular profile of chemo-resistance of myeloma stem cells.
Finally, Karin Vanderkerken (Brussels, Belgium) presented data of the 5TMM myeloma mouse model, which serves as a realistic pre-clinical model for myeloma (stem-) cell analysis. |
|
| 27 Oct 2008 by kirsten |
return to newslist
|
|
